Search

Displaying results 5151 - 5160 of 7540 in total
  1. Drug

    Olinciguat

    go.drugbank.com/drugs/DB15238
    Investigational

    Olinciguat is under investigation in clinical trial NCT03892499 (A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator

  2. Drug

    Monophosphothiamine

    go.drugbank.com/drugs/DB16023
    Experimental

    Mixtures: NEO CROMATON BICOMPLESSO
  3. Drug

    Olesoxime

    go.drugbank.com/drugs/DB05185
    Investigational

    For example, it has demonstrated the ability to prevent neurodegeneration, enhance nerve function and accelerate neuroregeneration following nerve trauma.[A3282,A253233]

    Synonyms: (EZ)-N-(CHOLEST-4-EN-3-YLIDENE)HYDROXYLAMINE
  4. Drug

    Polaprezinc

    go.drugbank.com/drugs/DB09221
    Investigational

    It is a zinc-related medicine approved for the first time in Japan, which has been clinically used to treat gastric ulcers [L1307, L1308]. … A study in 2013 showed that CO-administration of polaprezinc may be effective against small intestine mucosal injury associated with long-term aspirin therapy [A7840].

  5. Drug

    13-deoxydoxorubicin

    go.drugbank.com/drugs/DB05706
    Investigational

    GPX-100 is an anthracycline anticancer drug that belongs to the family of drugs called antitumor antibiotics.

  6. Drug

    Nomifensine

    go.drugbank.com/drugs/DB04821
    ApprovedWithdrawn

    The approved application holder removed Merital capsules from the market on January 23, 1986. … Approval of the NDA for Merital capsules was withdrawn on March 20, 1992 (see the Federal Register of March 20, 1992 (57 FR 9729)). Also withdrawn from the Canadian and UK markets.

  7. Drug

    FavId

    go.drugbank.com/drugs/DB05249
    Investigational

    FavId, is an active immunotherapy that is based upon unique genetic information extracted from a patient's tumor.

  8. Drug

    LJP 1082

    go.drugbank.com/drugs/DB05446
    Experimental

    LJP 1082 is a Toleragen that is designed to shut down the B cells that produce antibodies to ß2 GP1. … To date, our scientists have shown that approximately 90% of patients studied with antibody-mediated thrombosis have antibodies that bind to this region.

  9. Drug

    PF-05241328

    go.drugbank.com/drugs/DB15124
    Investigational

    Which Will Not Have Any Pharmacological Activity). … PF-05241328 is under investigation in clinical trial NCT01165736 (To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound

  10. Drug

    Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells

    go.drugbank.com/drugs/DB15740
    Investigational

    Currently, OM-MSCs does not have wide application as there is not yet a standard and unambiguous protocol for OM-MSC collection, isolation, and therapeutic application. … Human olfactory mucosa-derived mesenchymal stem cells (OM-MSCs) reside in an accessible location of the nasal cavity and have properties of multipotency and high proliferation, which contributes to high